Avoid These 2 Coronavirus Innovator Stocks in November

Inovio Pharmaceuticals (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) are both small biotech companies that have made names for themselves by initiating coronavirus vaccine projects. So far, both have made some progress, and early clinical trials proceeded largely as planned. Their innovative vaccine technologies hold tremendous potential, and their futures may be bright. But neither company has any therapies or vaccines that are currently approved for sale, and it's a safe bet that neither will be the first to commercialize a coronavirus vaccine.

On the other hand, competitors like Pfizer (NYSE: PFE) and BioNTech, (NASDAQ: BNTX), Moderna, (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) are approaching the final stages of the clinical trial process. It's highly likely that more than one of these companies will succeed in fielding a coronavirus vaccine, while Inovio and Vaxart are still figuring out if their candidates are safe or effective enough to proceed. That's bad news for the pair, but it's far from the only thing which might send their stock prices into a spiral this month.

Image source: Getty Images.

Source Fool.com